B. Riley Securities Maintains Buy on Altimmune, Announces $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Mayank Mamtani maintains a Buy rating on Altimmune (NASDAQ:ALT) and sets a price target of $20.
February 13, 2024 | 11:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B. Riley Securities maintains a Buy rating on Altimmune with a price target of $20.
The maintenance of a Buy rating and the setting of a $20 price target by a reputable analyst firm like B. Riley Securities could lead to increased investor confidence in Altimmune. This positive outlook is likely to influence the stock's short-term price positively, as investors may be encouraged by the analyst's confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100